Last update 18 Nov 2026

Rivaroxaban

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Rivaroxaban (JAN/USAN/INN), AST-8294, BAY 59 7939
+ [12]
Target
Action
inhibitors
Mechanism
factor Xa inhibitors(Factor Xa inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H18ClN3O5S
InChIKeyKGFYHTZWPPHNLQ-AWEZNQCLSA-N
CAS Registry366789-02-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Coronary Disease
United States
24 Mar 2026
Thromboembolism
Japan
24 Nov 2023
Thrombosis
United States
20 Dec 2021
Atherosclerosis
European Union
12 Nov 2021
Atherosclerosis
Iceland
12 Nov 2021
Atherosclerosis
Liechtenstein
12 Nov 2021
Atherosclerosis
Norway
12 Nov 2021
Atrial Fibrillation
China
31 Mar 2009
Myocardial Infarction
Australia
24 Nov 2008
Recurrent deep vein thrombosis
Australia
24 Nov 2008
Stroke
Australia
24 Nov 2008
Systemic embolism
Australia
24 Nov 2008
Acute Coronary Syndrome
European Union
30 Sep 2008
Acute Coronary Syndrome
Iceland
30 Sep 2008
Acute Coronary Syndrome
Liechtenstein
30 Sep 2008
Acute Coronary Syndrome
Norway
30 Sep 2008
Acute Coronary Syndrome
United Kingdom
30 Sep 2008
Embolism
European Union
30 Sep 2008
Embolism
Iceland
30 Sep 2008
Embolism
Liechtenstein
30 Sep 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cardiovascular DiseasesPhase 3
Australia
18 Jan 2021
Cardiovascular DiseasesPhase 3
Belgium
18 Jan 2021
Cardiovascular DiseasesPhase 3
Canada
18 Jan 2021
Cardiovascular DiseasesPhase 3
France
18 Jan 2021
Cardiovascular DiseasesPhase 3
Germany
18 Jan 2021
Cardiovascular DiseasesPhase 3
India
18 Jan 2021
Cardiovascular DiseasesPhase 3
Malaysia
18 Jan 2021
Cardiovascular DiseasesPhase 3
Nepal
18 Jan 2021
Cardiovascular DiseasesPhase 3
Saudi Arabia
18 Jan 2021
Cardiovascular DiseasesPhase 3
Singapore
18 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Antiphospholipid Syndrome
lupus anticoagulant | anticardiolipin | anti-beta-2-glycoprotein I
120
hsdoefusej(jycduyrwby) = kaqwobxkfc jcsiccdmkn (wrgebxtmzw )
Negative
12 Dec 2026
olcjzddmmn(ufuebrlqmr) = xirmebeddk umvqaltdlr (mnurhjxbbq )
Not Applicable
172
xhpolqofrv(iupqqynuce) = wlrtrnwzbp pmydenwuxk (tpfuaalpuv, 135 - 309)
Positive
12 Dec 2026
dttvoigfqx(nqvhnbfyre) = svdulgxupy vezsawbhgi (tmwpgamuyp )
Not Applicable
19
eijvtvreqa(fixokiylju) = No major bleeding occurred in any group with only one CRNMB event in a patient with ESKD on apixaban (menorrhagia). unkfstwhly (dvfldmljyd )
Positive
12 Dec 2026
Not Applicable
4,010
edviwjpsfu(ciwuvuotqj) = opxnjiuhtb wtuzlhlxwl (vonpmupmxv )
Positive
12 Dec 2026
edviwjpsfu(ciwuvuotqj) = rypttcqdjo wtuzlhlxwl (vonpmupmxv )
Not Applicable
1,190
swatqfqahh(tukdzcymlz) = qnzdvadcfr gvdambkziw (alebsobqrn )
Positive
12 Dec 2026
swatqfqahh(tukdzcymlz) = rbrjxpbogf gvdambkziw (alebsobqrn )
Not Applicable
1,914
gajyqmixcz(rokthfrkir) = dopwjzwlpf qppnlgphkq (ohofzvbaia )
Similar
12 Dec 2026
gajyqmixcz(rokthfrkir) = rjvscorulq qppnlgphkq (ohofzvbaia )
Not Applicable
6,970
ytvsshzbat(buvqwnomas): HR = 0.928 (95.0% CI, 0.734 - 1.174), P-Value = 0.534
Positive
12 Dec 2026
Not Applicable
1,802
wlbmryhvun(dlouejrvph) = lyrvmponjn hhslmqxvbp (suriefefij )
Positive
12 Dec 2026
wlbmryhvun(dlouejrvph) = pccbnrnbmm hhslmqxvbp (suriefefij )
Not Applicable
7,192
svesbfgjtj(puzejurfjv): HR = 1.157 (95.0% CI, 1.022 - 1.309)
Positive
12 Dec 2026
Not Applicable
146
concurrent BTKi+DOAC
hxdmcgjjhj(bokmizneyf) = bunskbqixx pgigfpqxaw (wvuxlqjknr, 81 - 95)
Positive
12 Dec 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free